327 related articles for article (PubMed ID: 21847041)
41. Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.
Tanaka K; Hata A; Kaji R; Fujita S; Otoshi T; Fujimoto D; Kawamura T; Tamai K; Takeshita J; Matsumoto T; Monden K; Nagata K; Otsuka K; Nakagawa A; Tachikawa R; Otsuka K; Tomii K; Katakami N
J Thorac Oncol; 2013 Jul; 8(7):892-8. PubMed ID: 23591159
[TBL] [Abstract][Full Text] [Related]
42. Rationale for treatment and study design of tailor: a randomized phase III trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor receptor mutations.
Farina G; Longo F; Martelli O; Pavese I; Mancuso A; Moscetti L; Labianca R; Bertolini A; Cortesi E; Farris A; Fagnani D; Locatelli MC; Valmadre G; Ardizzoia A; Tomirotti M; Rulli E; Garassino MC; Scanni A
Clin Lung Cancer; 2011 Mar; 12(2):138-41. PubMed ID: 21550561
[TBL] [Abstract][Full Text] [Related]
43. Erlotinib plus bevacizumab as an effective treatment for leptomeningeal metastases from EGFR mutation-positive non-small cell lung cancer.
Sakata Y; Kawamura K; Shingu N; Ichikado K
Lung Cancer; 2016 Sep; 99():120-2. PubMed ID: 27565925
[TBL] [Abstract][Full Text] [Related]
44. Metastatic brain tumors from non-small cell lung cancer with EGFR mutations: distinguishing influence of exon 19 deletion on radiographic features.
Sekine A; Kato T; Hagiwara E; Shinohara T; Komagata T; Iwasawa T; Satoh H; Tamura K; Kasamatsu T; Hayashihara K; Saito T; Takahashi H; Ogura T
Lung Cancer; 2012 Jul; 77(1):64-9. PubMed ID: 22335887
[TBL] [Abstract][Full Text] [Related]
45. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
Kim ST; Uhm JE; Lee J; Sun JM; Sohn I; Kim SW; Jung SH; Park YH; Ahn JS; Park K; Ahn MJ
Lung Cancer; 2012 Jan; 75(1):82-8. PubMed ID: 21684626
[TBL] [Abstract][Full Text] [Related]
46. Effectiveness and cost-effectiveness of erlotinib versus gefitinib in first-line treatment of epidermal growth factor receptor-activating mutation-positive non-small-cell lung cancer patients in Hong Kong.
Lee VW; Schwander B; Lee VH
Hong Kong Med J; 2014 Jun; 20(3):178-86. PubMed ID: 24281768
[TBL] [Abstract][Full Text] [Related]
47. The use of first-generation tyrosine kinase inhibitors in patients with NSCLC and somatic EGFR mutations.
Riely GJ
Lung Cancer; 2008 Jun; 60 Suppl 2():S19-22. PubMed ID: 18513580
[TBL] [Abstract][Full Text] [Related]
48. [
Traxl A; Beikbaghban T; Wanek T; Kryeziu K; Pirker C; Mairinger S; Stanek J; Filip T; Sauberer M; Kuntner C; Berger W; Langer O
Nucl Med Biol; 2017 Sep; 52():7-15. PubMed ID: 28575795
[TBL] [Abstract][Full Text] [Related]
49. Subsequent brain metastasis responses to epidermal growth factor receptor tyrosine kinase inhibitors in a patient with non-small-cell lung cancer.
Gounant V; Wislez M; Poulot V; Khalil A; Lavole A; Cadranel J; Milleron B
Lung Cancer; 2007 Dec; 58(3):425-8. PubMed ID: 17945377
[TBL] [Abstract][Full Text] [Related]
50. A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells.
Molina-Vila MA; Bertran-Alamillo J; Reguart N; Taron M; Castellà E; Llatjós M; Costa C; Mayo C; Pradas A; Queralt C; Botia M; Pérez-Cano M; Carrasco E; Tomàs M; Mate JL; Moran T; Rosell R
J Thorac Oncol; 2008 Nov; 3(11):1224-35. PubMed ID: 18978556
[TBL] [Abstract][Full Text] [Related]
51. First case of A859T epidermal growth factor receptor mutation responding to erlotinib.
Le Maignan L; Mirebeau-Prunier D; Vervueren L; Jeanfaivre T; Urban T; Hureaux J
J Thorac Oncol; 2011 Mar; 6(3):639-40. PubMed ID: 21317745
[No Abstract] [Full Text] [Related]
52. Phase II trial of erlotinib in patients with advanced non‑small‑cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics.
Motoshima K; Nakamura Y; Sano K; Ikegami Y; Ikeda T; Mizoguchi K; Takemoto S; Fukuda M; Nagashima S; Iida T; Tsukamoto K; Kohno S
Cancer Chemother Pharmacol; 2013 Dec; 72(6):1299-1304. PubMed ID: 24121455
[TBL] [Abstract][Full Text] [Related]
53. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.
Riely GJ; Pao W; Pham D; Li AR; Rizvi N; Venkatraman ES; Zakowski MF; Kris MG; Ladanyi M; Miller VA
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):839-44. PubMed ID: 16467097
[TBL] [Abstract][Full Text] [Related]
54. Combined treatment with erlotinib and a transforming growth factor-β type I receptor inhibitor effectively suppresses the enhanced motility of erlotinib-resistant non-small-cell lung cancer cells.
Serizawa M; Takahashi T; Yamamoto N; Koh Y
J Thorac Oncol; 2013 Mar; 8(3):259-69. PubMed ID: 23334091
[TBL] [Abstract][Full Text] [Related]
55. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations.
Inoue A; Suzuki T; Fukuhara T; Maemondo M; Kimura Y; Morikawa N; Watanabe H; Saijo Y; Nukiwa T
J Clin Oncol; 2006 Jul; 24(21):3340-6. PubMed ID: 16785471
[TBL] [Abstract][Full Text] [Related]
56. Targeted therapy in patients with non-small cell lung cancer previously treated with chemotherapy.
Drobnienė M; Cicėnienė A; Zelvienė TP; Grigienė R; Lachej N; Steponavičienė L; Aleknavičius E
Medicina (Kaunas); 2011; 47(9):520-5. PubMed ID: 22156604
[TBL] [Abstract][Full Text] [Related]
57. Erlotinib for the treatment of brain metastases in non-small cell lung cancer.
Brower JV; Robins HI
Expert Opin Pharmacother; 2016; 17(7):1013-21. PubMed ID: 26967582
[TBL] [Abstract][Full Text] [Related]
58. Molecular imaging with 11C-PD153035 PET/CT predicts survival in non-small cell lung cancer treated with EGFR-TKI: a pilot study.
Meng X; Loo BW; Ma L; Murphy JD; Sun X; Yu J
J Nucl Med; 2011 Oct; 52(10):1573-9. PubMed ID: 21903741
[TBL] [Abstract][Full Text] [Related]
59. CT findings in non-small-cell lung cancer patients treated with gefitinib or erlotinib.
Na II; Choe du H; Kim CH; Park SH; Park JH; Lee JC
J Cancer Res Ther; 2012; 8(2):247-53. PubMed ID: 22842370
[TBL] [Abstract][Full Text] [Related]
60. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib.
Punnoose EA; Atwal S; Liu W; Raja R; Fine BM; Hughes BG; Hicks RJ; Hampton GM; Amler LC; Pirzkall A; Lackner MR
Clin Cancer Res; 2012 Apr; 18(8):2391-401. PubMed ID: 22492982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]